European CHMP Issues Positive Opinion On Cymbalta For The Treatment Of Generalised Anxiety Disorder Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMEA) has issued a positive opinion supporting the approval of Cymbalta� (duloxetine hydrochloride) for the treatment of Generalised Anxiety Disorder (GAD).
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
